These findings have therapeutic implications as they indicate that alternative NF-κB inhibitors may enhance the anticancer efficacy of antimetabolic drugs, thus providing a strong rationale for the development of new molecules targeting RelB for therapeutic intervention in cancer. Here, NFKB1 is linked to cancer.